期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.644592
关键词
tuberous sclerosis gene mutation; RAR beta; vitamin A metabolism; retinoic acid; rapamycin
类别
资金
- [JP:TUDFO/51757-1/2019-ITM]
- [2020-4.1.1-TKP2020]
- [GINOP 2.3.2-15-2016-00022]
- [EFOP-3.6.1-16-2016-00004]
- [GINOP2.3.3-15-2016-00012 HECRIN]
The study found that TSC mutation leads to dysregulation of vitamin A metabolic enzymes and downregulation of RARβ, while RA can restore RARβ levels and limit cell migration with minimal effect on proliferation. Combination of RA and rapamycin can normalize enzyme expression and activity, restore RARβ expression, and reduce cell proliferation and migration.
Background: Mutation in a tuberous sclerosis gene (TSC1 or 2) leads to continuous activation of the mammalian target of rapamycin (mTOR). mTOR activation alters cellular including vitamin A metabolism and retinoic acid receptor beta (RAR beta) expression. The goal of the present study was to investigate the molecular connection between vitamin A metabolism and TSC mutation. We also aimed to investigate the effect of the FDA approved drug rapamycin and the vitamin A metabolite retinoic acid (RA) in cell lines with TSC mutation. Methods: Expression and activity of vitamin A associated metabolic enzymes and RAR beta were assessed in human kidney angiomyolipoma derived cell lines, primary lymphangioleiomyomatosis (LAM) tissue derived LAM cell lines. RAR beta protein levels were also tested in primary LAM lung tissue sections. TaqMan arrays, enzyme activities, qRT-PCRs, immunohistochemistry, immunofluorescent staining, and western blotting were performed and analysed. The functional effects of retinoic acid (RA) and rapamycin were tested in a scratch and a BrDU assay to assess cell migration and proliferation. Results: Metabolic enzyme arrays revealed a general deregulation of many enzymes involved in vitamin A metabolism including aldehyde dehydrogenases (ALDHs), alcohol dehydrogenases (ADHs) and Cytochrome P450 2E1 (CYP2E1). Furthermore, RAR beta downregulation was a characteristic feature of all TSC-deficient cell lines and primary tissues. Combination of the two FDA approved drugs -RA for acute myeloid leukaemia and rapamycin for TSC mutation- normalised ALDH and ADH expression and activity, restored RAR beta expression and reduced cellular proliferation and migration. Conclusion: Deregulation of vitamin A metabolizing enzymes is a feature of TSC mutation. RA can normalize RAR beta levels and limit cell migration but does not have a significant effect on proliferation. Based on our data, translational studies could confirm whether combination of RA with reduced dosage of rapamycin would have more beneficial effects to higher dosage of rapamycin monotherapy meanwhile reducing adverse effects of rapamycin for patients with TSC mutation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据